Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo

• Published in: Biochemical pharmacology Vol. 64; no. 7; pp. 1079 - 1090
• Main Authors: Sasakawa, Yuka, Naoe, Yoshinori, Inoue, Takeshi, Sasakawa, Tatsuya, Matsuo, Masahiko, Manda, Toshitaka, Mutoh, Seitaro
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.10.2002; Elsevier Science
• Subjects: Acetylation; Animals; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibiotics, Antineoplastic - pharmacology; Antibiotics, Antineoplastic - therapeutic use; Antineoplastic agents; Apoptosis; Biological and medical sciences; Cell Cycle - drug effects; Cell Differentiation - drug effects; Chemotherapy; Cholecalciferol - pharmacology; Cyclin-Dependent Kinase Inhibitor p21; Cyclins - biosynthesis; Cyclins - genetics; Depsipeptides; Disease Models, Animal; FK228; Gelsolin - biosynthesis; Gelsolin - genetics; Histone deacetylase inhibitor; Histone Deacetylase Inhibitors; Histones - metabolism; Humans; Leukemia - pathology; Lymphoma; Lymphoma - drug therapy; Lymphoma - pathology; Medical sciences; Mice; Mice, SCID; Neoplasm Transplantation; Peptides, Cyclic; Pharmacology. Drug treatments; Promoter Regions, Genetic - drug effects; Promoter Regions, Genetic - genetics; RNA, Messenger - biosynthesis; RNA, Messenger - drug effects; Tretinoin - pharmacology; U-937; U937 Cells; Xenograft Model Antitumor Assays; APL, acute promyelocytic leukemia; U-937; q-PCR, quantitative polymerase chain reaction; Lymphoma; vitamin D 3, 1α,25-dihydroxy-vitamin D 3; FK228; ChIP, chromatin immunoprecipitation; PE, phycoerythrin; Histone deacetylase inhibitor; ATRA, all- trans retinoic acid; HDAC, histone deacetylase; PTCL, peripheral T-cell lymphoma; TSA, trichostatin A; CTCL, cutaneous T-cell lymphoma; Antineoplastic agent; Human; Intraperitoneal administration; Rodentia; Enzyme inhibitor; Malignant hemopathy; In vitro; Biological activity; In vivo; Vertebrata; Chemotherapy; Mammalia; Treatment; Mouse; Lymphoproliferative syndrome; Animal; Established cell line; Mechanism of action; Tumor cell

FK228 [( E)-(1 S,4 S,10 S,21 R)-7-[( Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo-[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, depsipeptide] is a novel histone deacetylase inhibitor that shows therapeutic efficacy in Phase I trials of patients with malignant...